Can Delcath’s HEPZATO redefine the treatment window for metastatic uveal melanoma?
New subgroup data on HEPZATO highlights improved survival in low-burden metastatic uveal melanoma. Find out what this changes in clinical strategy.
Medical Devices & Diagnostics